Literature DB >> 15194078

siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.

Mark S Duxbury1, Hiromichi Ito, Michael J Zinner, Stanley W Ashley, Edward E Whang.   

Abstract

BACKGROUND: The c-Src tyrosine kinase is a determinant of malignant cellular behavior in a variety of human cancers. We sought to determine the effect of suppressing c-Src expression on pancreatic adenocarcinoma chemosensitivity to gemcitabine. STUDY
DESIGN: PANC1, MIAPaCa2, BxPC3, and Capan2 pancreatic adenocarcinoma cell lines were studied. Expression of c-Src was determined by Western blot analysis. c-Src kinase activity was determined by in vitro kinase assay. RNA interference was used to suppress c-Src expression. Gemcitabine-induced cytotoxicity was determined by tetrazolium reduction assay and caspase profiling was performed. The effect of Src-specific siRNA on Akt activity was quantified.
RESULTS: Src expression and kinase activity in cell lines were directly correlated with gemcitabine chemoresistance. c-Src-specific siRNA suppressed c-Src expression and kinase activity. c-Src-specific siRNA increased gemcitabine-induced, caspase-mediated apoptosis. Akt activity was decreased by suppression of c-Src expression.
CONCLUSIONS: c-Src is a determinant of pancreatic adenocarcinoma chemoresistance and represents a potential target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194078     DOI: 10.1016/j.jamcollsurg.2004.01.037

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  28 in total

Review 1.  SRC: a century of science brought to the clinic.

Authors:  Alexey Aleshin; Richard S Finn
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

3.  Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Authors:  Nagathihalli S Nagaraj; M Kay Washington; Nipun B Merchant
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

4.  Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Authors:  Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

5.  Molecular predictors of gemcitabine response in pancreatic cancer.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2011-11-15

6.  Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.

Authors:  Divya Pathania; Yuting Kuang; Mario Sechi; Nouri Neamati
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

7.  Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.

Authors:  Bart M Maślikowski; Benjamin D Néel; Ying Wu; Lizhen Wang; Natalie A Rodrigues; Germain Gillet; Pierre-André Bédard
Journal:  BMC Cancer       Date:  2010-02-12       Impact factor: 4.430

8.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

9.  Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

Authors:  Martine Humbert; Nathalie Castéran; Sébastien Letard; Katia Hanssens; Juan Iovanna; Pascal Finetti; François Bertucci; Thomas Bader; Colin D Mansfield; Alain Moussy; Olivier Hermine; Patrice Dubreuil
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

10.  Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.

Authors:  O J Igwe
Journal:  Eur J Pain       Date:  2012-12-27       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.